Overview on published/presented data on MASH cirrhosis #LiverSky @bavenocoop.bsky.social

🖇️: authors.elsevier.com/sd/article/S...

📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)

👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3

🖇️ for explanation: authors.elsevier.com/sd/article/S...

📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)

👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3

🖇️ for explanation: authors.elsevier.com/sd/article/S...

🙏 for the organization 👌

@bavenocoop.bsky.social visiting the Japanese Society of Portal Hypertension

👀 at our auditorium

🙏 incredible hospitality

👉 See our 🇯🇵 friends at Baveno VIII

I am very sad. My mentor and friend, Jaume Bosch, just has passed away. Thanks for everything, I will miss you. I would always remember our last day together celebrating a journey we begin together @hospitalclinic.bsky.social @idibaps.bsky.social

🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation.

A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.

Rest in peace, Jaime

Adéu Jaume, GOAT of portal hypertension! What a loss!

I remember how privileged I felt when he visited Hemodinámica Hepática in 2019 and picked me up for lunch at Paco Meralgo.

Our last walk in Bern this Spring ...

doi.org/10.1097/HEP....

@majathiele.bsky.social @reibergerthomas.bsky.social @aasldnews.bsky.social @bavenocoop.bsky.social

Monitoring resmetirom by LSM - asking for the moon?
Oftentimes mentioned but even more often forgotten:
❗️Random variation of LSM by VCTE exceeds 25%
👉🔽 LSM >25% often by chance, same for 'unchanged' or increases
👉No substitute for clinical judgement
#LiverSky @georg-semmler.bsky.social
🔗👇

How often do u get asked to “clear” patients w/cirrhosis for surgery?
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...

📢 First @easlnews.bsky.social CPG on surgery in cirrhosis presented today together with the one on TIPS!
🤝 See you at 10:30 Erlinger Room!
@bavenocoop.bsky.social #LiverSky

👏
Standing ovations for @bavenocoop.bsky.social's @docberza.bsky.social at the @easlnews.bsky.social Community Award presentation.
Chapeau! What a wonderful person!
#LiverSky

Thirteen years ago when I was still an M.D. student, I was invited for my first oral presentation at an @easlnews.bsky.social event.
🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky

‼️Following first hepatic decompensation, patients with severe #AATD have a higher risk of complications vs. other aetiologies
👉Early listing for liver transplantation. #LiverSky

🔗https://doi.org/10.1016/j.jhepr.2024.101308

@easlnews.bsky.social @jhepatology.bsky.social

Have you ever screened 25 patients for a single trial and randomized nearly as many?

Vienna Hepatic Hemodynamic Lab advancing drug development for portal hypertension. Eager to see results ...

#LiverSky @bavenocoop.bsky.social

Conversation with the Customs employee at the airport when entering the U.S. for a 1-day meeting:
When is your flight back? - Tomorrow. - So they pay you well. - No, I'm in academia. - Oh, so they own you. 😋

@bavenocoop.bsky.social Research Committee Baveno VIII Pre-Symposium, here we go!
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky

❤️ @easlnews.bsky.social & @bavenocoop.bsky.social friends

I had the privilege to visit two top liver destinations in 🇪🇺 in the last couple of days - 🙏 enormous hospitality
🇨🇭Bern @docberza.bsky.social et al
🇮🇹Padova Alberto Zanetto et al
👀Summary slides attached!
#liversky

Challenge for #liversky :
Monitoring regression/progression on resmetirom & deciding on alternative treatments
▶️ AASLD provided guidance
▶️ We commented on the role of LSM: doi.org/10.1097/HEP....
‼️ Random variation in LSM >25%
‼️ Consider overall medical benefit (e.g., GLP-1)

Aaah, I was looking for this tag! Newbie thanks!

👋 Bluesky

📰 Review: Non-invasive assessment of portal hypertension: Liver stiffness and beyond

@docberza.bsky.social & @juanabraldes.bsky.social summarising the evidence for the upcoming @bavenocoop.bsky.social VIII in @jhepatology.bsky.social Reports

🔗https://doi.org/10.1016/j.jhepr.2024.101300